Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better?
about
Tuberculosis innovations mean little if they cannot save livesAn evaluation of automated chest radiography reading software for tuberculosis screening among public- and private-sector patients.Treatment decisions and mortality in HIV-positive presumptive smear-negative TB in the Xpert™ MTB/RIF era: a cohort study.Implementation of the Xpert MTB/RIF assay for tuberculosis in Mongolia: a qualitative exploration of barriers and enablersPerformance of a lateral flow immunochromatography test for the rapid diagnosis of active tuberculosis in a large multicentre study in areas with different clinical settings and tuberculosis exposure levels.Addressing the challenges of diagnostics demand and supply: insights from an online global health discussion platformThe impact of the roll-out of rapid molecular diagnostic testing for tuberculosis on empirical treatment in Cape Town, South AfricaFAST implementation in Bangladesh: high frequency of unsuspected tuberculosis justifies challenges of scale-up.The paradigm shift to end tuberculosis. Are we ready to assume the changes?Diagnosis of Tuberculosis in HIV Co-infected Individuals: Current Status, Challenges and Opportunities for the Future.FluoroType MTB system for the detection of pulmonary tuberculosisDrug-resistant tuberculosis in 2017: at a crossroads.Molecular diagnosis of tuberculosis: we need solutions that span the healthcare value chain.The New Xpert MTB/RIF Ultra: Improving Detection of Mycobacterium tuberculosis and Resistance to Rifampin in an Assay Suitable for Point-of-Care Testing.Scaling-up the Xpert MTB/RIF assay for the detection of tuberculosis and rifampicin resistance in India: An economic analysis.Evaluation of the Abbott RealTime MTB and RealTime MTB INH/RIF Assays for Direct Detection of Mycobacterium tuberculosis Complex and Resistance Markers in Respiratory and Extrapulmonary Specimens.Tuberculosis prevention must integrate technological and basic care innovation.Genotyping Multi-Drug Resistant M. tuberculosis from Primary Sputum and Decontaminated Sediment with an Integrated Microfluidic Amplification Microarray.Current use and acceptability of novel diagnostic tests for active tuberculosis: a worldwide survey.RPA using a multiplexed cartridge for low cost point of care diagnostics in the field.Surrogate endpoints in global health research: still searching for killer apps and silver bullets?Catalysing progressive uptake of newer diagnostics by health care providers through outreach and education in four major cities of India.Multidisease testing for HIV and TB using the GeneXpert platform: A feasibility study in rural Zimbabwe.Incremental cost-effectiveness of the second Xpert MTB/RIF assay to detect Mycobacterium tuberculosis.Xpert implementation in challenging scenarios: a brand-new car running on the same bumpy old roads.Diagnostic accuracy evaluation of the conventional and molecular tests for Spinal Tuberculosis in a cohort, head-to-head study.Using routinely collected laboratory data to identify high rifampicin-resistant tuberculosis burden communities in the Western Cape Province, South Africa: A retrospective spatiotemporal analysisThe implementation of Xpert MTB/RIF assay for diagnosis of tuberculosis in Nepal: A mixed-methods analysisTuberculosis
P2860
Q33627409-0A8E0582-D1A9-4D82-ADB9-703F328CD77DQ33768767-DD08A136-8416-46FB-A41A-21F0E7E6971FQ33808388-D93E7A0A-B4DD-4C42-A31E-E0E48F2E3F0EQ33906816-0E2F924E-AE82-4219-BD31-96E84D14514BQ37528171-F70D1ED1-3D42-4FAC-9B4A-72F10D8D87D5Q37659918-49676495-FB5C-48F1-B395-D97572A1DE82Q38399097-9B23CA2D-CC90-4231-AA3C-95A98561657CQ38615927-110505A5-3616-4BD9-93AB-1288BD75BBA8Q38676708-E3D49D68-B081-483D-B1CE-A7A4155E3D30Q38682808-9DF65658-EE59-4140-872A-61CA71072B9BQ39315338-25F56B05-EFEB-43D0-9212-0BDBF2F627EEQ40273120-7D3AEBCD-124B-4B7D-91F2-0BCB401E90F7Q40454569-9215A191-1580-42BD-9AF2-5E4C3F928F4CQ41546193-55E012D2-12EC-4BFC-B4CA-91F9D3796371Q41572739-3A90EC5C-BA31-4C89-9C82-FD2551E843ACQ41847472-6C9A8847-AD35-4CD3-A323-8A0AE4A55127Q42375717-75F279A5-F917-4E35-89DA-BAF92E2857AEQ47203483-1EBF1CED-849B-4259-AD05-8D82271C0E58Q47328040-C0CF6210-012F-45C9-8991-801E36427FCEQ49971594-D0D642E3-640F-408C-A829-720106E89F7CQ52614515-9AB1DD17-8630-435C-B35D-54D6CF7876E4Q52671839-150EF1D4-56D7-4C5E-B891-36843FDECE57Q52677086-93593E6C-C543-45FA-A1E5-69DA225E32EDQ53690300-90355F91-FF6F-4F25-81CA-96ACB92E1E92Q55040458-112AED8B-95B8-4144-9770-AABC332EFFECQ55362899-2101BF9A-D08B-444D-BA76-21616E854DB7Q58731377-A9109EF6-496E-4BF0-90AE-2A8112C3D8BFQ58791284-948F9678-3056-47D3-B959-27CE0254B161Q59200569-5764FB1E-0539-41F4-8CD5-55BDF5696FF9
P2860
Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better?
description
2016 nî lūn-bûn
@nan
2016 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
name
Development, roll-out and impa ...... arnt and how can we do better?
@ast
Development, roll-out and impa ...... arnt and how can we do better?
@en
Development, roll-out and impa ...... arnt and how can we do better?
@nl
type
label
Development, roll-out and impa ...... arnt and how can we do better?
@ast
Development, roll-out and impa ...... arnt and how can we do better?
@en
Development, roll-out and impa ...... arnt and how can we do better?
@nl
prefLabel
Development, roll-out and impa ...... arnt and how can we do better?
@ast
Development, roll-out and impa ...... arnt and how can we do better?
@en
Development, roll-out and impa ...... arnt and how can we do better?
@nl
P2093
P2860
P50
P921
P3181
P1476
Development, roll-out and impa ...... arnt and how can we do better?
@en
P2093
Catharina C Boehme
Chris Isaacs
Heidi Albert
P2860
P304
P3181
P356
10.1183/13993003.00543-2016
P407
P5008
P577
2016-08-01T00:00:00Z